Cellectar Biosciences, Inc., formerly Novelos Therapeutics, Inc., is a clinical stage biopharmaceutical company. The Company is engaged in developing phospholipid ether-drug conjugates (PDCs) for the treatment and diagnostic imaging of cancer. Its research and development program is based on its PDC cancer targeting delivery platform. Its pipeline consists of pre-clinical and clinical product candidates, including radiotherapeutic and chemotherapeutic PDC's. The Company's PDC product portfolio includes CLR 131, which is designed to deliver cytotoxic (cell-killing) radiation directly and selectively to cancer cells and cancer stem cells; CLR 125, which is for the treatment of micro metastatic disease; CLR 124, which is a cancer-targeting positron emission tomography (PET) imaging PDC; CLR 1502, which is for intraoperative tumor margin illumination and non-invasive tumor imaging, and CTX Product Portfolio, including CLR 1601-PTX, CLR 1602-PTX and CLR 1603-PTX product candidates.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Symbol: NASDAQ:CLRB
- CUSIP: N/A
- Web: www.cellectar.com
Capitalization:- Market Cap: $21.69 million
- Outstanding Shares: 13,462,000
Average Prices:- 50 Day Moving Avg: $1.97
- 200 Day Moving Avg: $1.86
- 52 Week Range: $1.06 - $4.58
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -1.90
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: $1.22 per share
- Price / Book: 1.39
Profitability:- EBIDTA: ($9,090,000.00)
- Return on Equity: -48.85%
- Return on Assets: -31.41%
Debt:- Current Ratio: 4.32%
- Quick Ratio: 4.32%
Misc:- Average Volume: 337,219 shs.
- Beta: 0.58
- Short Ratio: 3.49
Frequently Asked Questions for Cellectar Biosciences (NASDAQ:CLRB)
What is Cellectar Biosciences' stock symbol?
Cellectar Biosciences trades on the NASDAQ under the ticker symbol "CLRB."
How were Cellectar Biosciences' earnings last quarter?
Cellectar Biosciences Inc (NASDAQ:CLRB) released its earnings results on Thursday, May, 11th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.23) by $0.01. View Cellectar Biosciences' Earnings History.
Where is Cellectar Biosciences' stock going? Where will Cellectar Biosciences' stock price be in 2017?
3 analysts have issued 1 year target prices for Cellectar Biosciences' shares. Their predictions range from $2.70 to $2.70. On average, they anticipate Cellectar Biosciences' share price to reach $2.70 in the next year. View Analyst Ratings for Cellectar Biosciences.
Who are some of Cellectar Biosciences' key competitors?
Some companies that are related to Cellectar Biosciences include Burcon NutraScience Corp (BUR), Nivalis Therapeutics (NVLS), Chiasma (CHMA), Histogenics Corp (HSGX), Threshold Pharmaceuticals (THLD), KaloBios Pharmaceuticals (KBIO), Can Fite Biopharma Ltd (CANF), Alcobra Ltd (ADHD), Dimension Therapeutics (DMTX), Viking Therapeutics (VKTX), Catabasis Pharmaceuticals (CATB), Mirna Therapeutics (MIRN), Aldeyra Therapeutics (ALDX), Ocera Therapeutics (OCRX), Marinus Pharmaceuticals (MRNS), Pain Therapeutics (PTIE), Cytori Therapeutics (CYTX) and PLx Pharma (PLXP).
How do I buy Cellectar Biosciences stock?
Shares of Cellectar Biosciences can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Cellectar Biosciences stock cost?
One share of Cellectar Biosciences stock can currently be purchased for approximately $1.69.
Earnings History for Cellectar Biosciences (NASDAQ:CLRB)Earnings History by Quarter for Cellectar Biosciences (NASDAQ:CLRB)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 5/11/2017 | Q1 2017 | ($0.23) | ($0.24) | | | View | N/A |  |
| 3/15/2017 | Q4 2016 | ($0.23) | ($0.35) | | | View | N/A | |
| 11/10/2016 | Q3 2016 | ($0.20) | ($0.43) | | | View | N/A | |
| 8/11/2016 | Q2 2016 | ($0.40) | ($0.49) | | | View | N/A | |
| 11/12/2015 | Q315 | | ($0.25) | | | View | Listen | |
| 8/12/2015 | Q215 | | ($0.30) | | | View | Listen | |
| 5/21/2015 | Q115 | | ($0.30) | | | View | Listen | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Cellectar Biosciences (NASDAQ:CLRB)Current Year EPS Consensus Estimate: $-0.95 EPS
Next Year EPS Consensus Estimate: $-0.89 EPS
Dividend History for Cellectar Biosciences (NASDAQ:CLRB)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Cellectar Biosciences (NASDAQ:CLRB)Insider Ownership Percentage: 15.45%
Institutional Ownership Percentage: 1.25%
Insider Trades by Quarter for Cellectar Biosciences (NASDAQ:CLRB)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 11/29/2016 | John Neis | Director | Buy | 333,333 | $1.49 | $496,666.17 | |
| 10/31/2016 | Richard Hertzberg | Insider | Sell | 21,000 | $2.03 | $42,630.00 | |
| 4/20/2016 | James V Caruso | CEO | Buy | 46,948 | $2.12 | $99,529.76 | |
| 4/20/2016 | Paul L Berns | Director | Buy | 117,371 | $2.12 | $248,826.52 | |
| 12/31/2015 | Awm Investment Company, Inc. | Major Shareholder | Sell | 100,000 | $0.69 | $69,000.00 | |
| 12/29/2015 | Awm Investment Company, Inc. | Major Shareholder | Sell | 82,847 | $0.69 | $57,164.43 | |
| 12/28/2015 | Awm Investment Company, Inc. | Major Shareholder | Sell | 367,966 | $0.73 | $268,615.18 | |
| 12/22/2015 | Awm Investment Company, Inc. | Major Shareholder | Sell | 7,938 | $0.90 | $7,144.20 | |
| 12/21/2015 | Awm Investment Company, Inc. | Major Shareholder | Sell | 27,621 | $0.92 | $25,411.32 | |
| 12/17/2015 | Awm Investment Company, Inc. | Major Shareholder | Sell | 71,225 | $0.87 | $61,965.75 | |
| 12/15/2015 | Awm Investment Company, Inc. | Major Shareholder | Sell | 44,965 | $0.82 | $36,871.30 | |
| 12/4/2015 | Awm Investment Company, Inc. | Major Shareholder | Sell | 50,950 | $1.06 | $54,007.00 | |
| 11/24/2015 | Awm Investment Company, Inc. | Major Shareholder | Sell | 173,802 | $1.24 | $215,514.48 | |
| 11/24/2015 | James V Caruso | CEO | Buy | 1,000 | $1.30 | $1,300.00 | |
| 11/20/2015 | Awm Investment Company, Inc. | Major Shareholder | Sell | 96,806 | $1.17 | $113,263.02 | |
| 11/20/2015 | James V Caruso | CEO | Buy | 1,000 | $1.16 | $1,160.00 | |
| 11/19/2015 | James V. Caruso | CEO | Buy | 4,000 | $1.45 | $5,800.00 | |
| 10/23/2015 | Awm Investment Company, Inc. | Major Shareholder | Sell | 8,866 | $2.00 | $17,732.00 | |
| 10/6/2015 | Awm Investment Company, Inc. | Major Shareholder | Sell | 2,554 | $2.00 | $5,108.00 | |
| 10/5/2015 | Awm Investment Company, Inc. | Major Shareholder | Sell | 7,500 | $2.04 | $15,300.00 | |
| 10/1/2015 | Awm Investment Company, Inc. | Major Shareholder | Sell | 27,940 | $2.05 | $57,277.00 | |
| 9/29/2015 | Awm Investment Company, Inc. | Major Shareholder | Sell | 24,801 | $2.36 | $58,530.36 | |
| 8/20/2014 | John Neis | Director | Buy | 268,711 | $3.75 | $1,007,666.25 | |
| 8/20/2014 | Simon Pedder | CEO | Buy | 13,300 | $3.75 | $49,875.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Cellectar Biosciences (NASDAQ:CLRB)
Latest Headlines for Cellectar Biosciences (NASDAQ:CLRB)
| Source: |
|
| Date | Headline |
|---|
 | Cellectar Biosciences Inc (CLRB) Stock Rating Lowered by ValuEngine
www.americanbankingnews.com - May 23 at 5:04 PM |
 | Three Abstracts on Dosing Regimens of Cellectar's CLR 131 in a Variety of Tumor Types Published in the 2017 ASCO ... - GlobeNewswire (press release)
globenewswire.com - May 18 at 4:16 PM |
 | Three Abstracts on Dosing Regimens of Cellectar’s CLR 131 in a Variety of Tumor Types Published in the 2017 ASCO Annual Meeting Proceedings
finance.yahoo.com - May 18 at 11:10 AM |
 | BRIEF-Cellectar Biosciences Q1 loss per share $0.24
www.reuters.com - May 12 at 9:56 PM |
| Edited Transcript of CLRB earnings conference call or presentation 11-May-17 8:30pm GMT
finance.yahoo.com - May 12 at 4:53 PM |
| Cellectar Biosciences Inc (CLRB) Issues Quarterly Earnings Results, Misses Expectations By $0.01 EPS
www.americanbankingnews.com - May 12 at 2:02 PM |
| Cellectar Biosciences Reports First Quarter 2017 Financial and Corporate Performance
finance.yahoo.com - May 11 at 4:58 PM |
 | Biotech Stocks on Investors' Radar -- BioMarin Pharma, Eyegate Pharma, Navidea Biopharma, and Cellectar Biosciences - PR Newswire (press release)
www.prnewswire.com - May 9 at 8:12 AM |
| Cellectar Biosciences to Host Conference Call on May 11, 2017 to Report First Quarter 2017 Financial Results and ... - Yahoo Finance
finance.yahoo.com - May 4 at 8:24 AM |
| Cellectar Biosciences (CLRB) Receives Media Sentiment Rating of 0.46
www.americanbankingnews.com - May 3 at 4:18 PM |
| Cellectar Biosciences to Host Conference Call on May 11, 2017 to Report First Quarter 2017 Financial Results and Corporate Performance
finance.yahoo.com - May 2 at 4:22 PM |
| Cellectar Biosciences (CLRB) Getting Somewhat Favorable Press Coverage, Report Shows
www.americanbankingnews.com - April 28 at 11:38 PM |
| Cellectar's Radiotherapeutic PDCs Demonstrate an Increased Survival Benefit Using Multiple Doses in Preclinical ... - Yahoo Finance
finance.yahoo.com - April 27 at 9:53 PM |
 | Cellectar Biosciences (CLRB) Says CLR 131 and CLR 125 Demonstrate Increased Survival Benefit Using Multiple Doses in Preclinical Studies
www.streetinsider.com - April 27 at 9:56 AM |
| Cellectar’s Radiotherapeutic PDCs Demonstrate an Increased Survival Benefit Using Multiple Doses in Preclinical Studies
finance.yahoo.com - April 27 at 9:56 AM |
| Cellectar Biosciences (CLRB) Announces Patents for PDC Optical Agents in Detection of Multiple Cancers
www.streetinsider.com - April 25 at 12:11 PM |
| Cellectar Biosciences Receives Additional U.S. Patents for PDC Optical Agents in the Detection of Multiple Cancers
finance.yahoo.com - April 25 at 12:11 PM |
| Cellectar Biosciences (CLRB) Earning Very Positive Media Coverage, Analysis Shows
www.americanbankingnews.com - April 22 at 9:55 AM |
| UPDATED: Cellectar Biosciences Strengthens Management Team with Appointment of John Friend, M.D. as Chief ... - GlobeNewswire (press release)
globenewswire.com - April 21 at 4:25 PM |
| UPDATED: Cellectar Biosciences Strengthens Management Team with Appointment of John Friend, M.D. as Chief Medical Officer
finance.yahoo.com - April 21 at 4:25 PM |
| Cellectar Biosciences (CLRB) Receives Japanese Patent for CLR 131 and CLR 125 - StreetInsider.com
www.streetinsider.com - April 19 at 9:22 PM |
| Cellectar Biosciences (CLRB) Receiving Favorable Press Coverage, Report Shows
www.americanbankingnews.com - April 19 at 7:40 AM |
| Cellectar Biosciences Receives Japanese Patent for CLR 131 and CLR 125 for the Treatment of Cancer Stem Cells
finance.yahoo.com - April 18 at 12:21 PM |
| Cellectar Biosciences (CLRB) Names John Friend, MD as CMO - StreetInsider.com
www.streetinsider.com - April 13 at 4:24 PM |
| Cellectar Biosciences (CLRB) Earning Very Favorable News Coverage, Study Finds
www.americanbankingnews.com - April 13 at 8:27 AM |
| Cellectar Biosciences Strengthens Management Team with Appointment of John Friend, M.D. as Chief Medical Officer
finance.yahoo.com - April 12 at 10:43 AM |
| Cellectar Biosciences Adds Industry Veterans Douglas Swirsky and Frederick Driscoll to Its Board of Directors
finance.yahoo.com - April 10 at 4:15 PM |
| Cellectar Biosciences (CLRB) Initiates NCI-Supported Phase II Trial of CLR 131 in MM and Other Blood Cancers
www.streetinsider.com - March 30 at 4:47 PM |
 | After Much Anticipation, Cellectar Biosciences Initiates NCI-Supported Phase II Trial of CLR 131 in Multiple Myeloma and Other Blood Cancers
us.rd.yahoo.com - March 30 at 4:47 PM |
| Cellectar Biosciences (CLRB) Granted Patent for PET Imaging PDC
www.streetinsider.com - March 21 at 9:38 PM |
| CELLECTAR BIOSCIENCES, INC. Financials
us.rd.yahoo.com - March 21 at 4:38 PM |
| Cellectar Biosciences Further Deepens Intellectual Property Portfolio with Patent Grant for PET Imaging PDC
us.rd.yahoo.com - March 21 at 11:40 AM |
| Edited Transcript of CLRB earnings conference call or presentation 15-Mar-17 10:00pm GMT
finance.yahoo.com - March 16 at 5:42 PM |
 | Cellectar Biosciences' (CLRB) CEO James Caruso on Q4 2016 Results - Earnings Call Transcript
seekingalpha.com - March 16 at 2:54 AM |
| CELLECTAR BIOSCIENCES, INC. Files SEC form 10-K, Annual Report
biz.yahoo.com - March 15 at 4:46 PM |
| Cellectar Biosciences Reports 2016 Company Performance and Continued Progress in First Quarter 2017
finance.yahoo.com - March 15 at 4:46 PM |
| Cellectar Biosciences (CLRB) Newly Issued Japanese Patent For PDC Optical Agents
www.streetinsider.com - March 15 at 6:41 AM |
 | Cellectar Biosciences Gets Japanese Patent (CLRB)
www.investopedia.com - March 14 at 4:13 PM |
| Cellectar Biosciences Secures Japanese Patent
us.rd.yahoo.com - March 14 at 4:13 PM |
| Newly Issued Japanese Patent For PDC Optical Agents Further Strengthens Cellectar Biosciences’ Intellectual Property Portfolio
us.rd.yahoo.com - March 14 at 12:49 PM |
| Cellectar Biosciences to Host Conference Call on March 15 to Report Fourth Quarter and Year-End 2016 Financial Results and Corporate Performance
finance.yahoo.com - March 9 at 4:56 PM |
| Expanding Its Strategic Relationship with Wisconsin Alumni Research Foundation (WARF), Cellectar Biosciences Executes New License Agreement
us.rd.yahoo.com - March 8 at 5:05 PM |
| Cellectar Biosciences Provides Phase I Trial Update of CLR 131 in Multiple Myeloma: Median Progression-Free …
finance.yahoo.com - February 27 at 3:43 PM |
| Cellectar Biosciences Provides Phase I Trial Update of CLR 131 in Multiple Myeloma: Median Progression-Free Survival Extends to 133 Days, Median Overall Survival Reaches 17.7 Months
us.rd.yahoo.com - February 27 at 3:43 PM |
| CELLECTAR BIOSCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
biz.yahoo.com - February 23 at 2:33 AM |
| Upon Successful Completion of Cohort 3, Cellectar Biosciences Initiates Fourth Cohort of Its Phase I Clinical Trial of CLR 131 in Multiple Myeloma
us.rd.yahoo.com - February 22 at 11:33 AM |
| UPDATE -- Cellectar Biosciences to Present at 2017 BIO CEO & Investor Conference
finance.yahoo.com - February 13 at 5:01 PM |
| Cellectar Biosciences' PDC Delivery Platform May Advance Treatment of Multiple Myeloma
finance.yahoo.com - February 13 at 5:01 PM |
| Cellectar Biosciences to Present at the 2nd Annual Disruptive Growth & Healthcare Conference
finance.yahoo.com - February 9 at 4:44 PM |
| Cellectar Biosciences to Present at 2017 BIO CEO & Investor Conference - GlobeNewswire (press release)
globenewswire.com - February 7 at 5:25 PM |
Cellectar Biosciences (CLRB) Chart for Wednesday, May, 24, 2017
